iShares MSCI Indonesia ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.47, while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while iShares MSCI Indonesia ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| EIDO | ZBH | |
|---|---|---|
52-Week High | $19.22 | $107.71 |
52-Week Low | $10.80 | $79.58 |
Market Cap | — | $18.55B |
Sector | — | Health |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
EIDO, the iShares MSCI Indonesia ETF, trades at $12.675, down 0.59% today, with a bearish technical signal from moving averages. The fund's valuation appears low, but financial data for the current period is unavailable. Recent news highlights Indonesia's economic initiatives and central bank policy shifts, while technical indicators show neutral oscillators and defined support at $12.
The outlook is mixed, with potential from Indonesia's GDP growth initiatives but weighed by foreign capital outflows and a strong financials weighting. Risks include currency volatility and dependence on commodity markets. Analyst sentiment is neutral due to weak price action despite attractive valuations.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Trailing returns across standard periods
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →